Spikes are activity by neurons, which the National Institute of Health describes as cells that use electrical and chemical signals to send information around the brain and to the body. In September, Neuralink said it received approval for recruitment for the human trial. The study uses a robot to surgically place a brain-computer interface (BCI) implant in a region of the brain that controls the intention to move, Neuralink said previously, adding that its initial goal is to enable people to control a computer cursor or keyboard using their thoughts alone.
There’s quite a difference between rapid prototyping on software/hardware versus the human body.
Musk’s approach to developing engineering advances has worked well in the software, aerospace, and vehicular industries. Development on inorganic things is much more predictable, we can isolate variables, and it is easier to understand cause & effect. If you screw up some software on an inorganic system, your program might crash, your rocket might explode, or your car won’t start. These risks can be anticipated and costed fairly well, therefore rapid prototyping has an acceptable risk/reward ratio in that environment.
The human body, on the other hand, is an extremely complex system that we still don’t fully understand. Each person is a unique variation on the model and that changes over time depending on upbringing, diet, exercise, and life experiences. Applying the same engineering approaches from inorganic industries has a much higher risk once you cross into the medical realm. If you have errors in a medical situation, you risk sickening, injuring, or even killing a person. The risk/reward ratio is skewed towards ensuring that human life is protected at all costs.
Using SpaceX as an example, the first three launches failed spectacularly and a fourth failure would have ended the business but fortunately the fourth test was a success. If you’re suggesting that we apply the same risk-taking to Neuralink, are you suggesting that it’s acceptable for the first three patients to die, as long as the fourth is a success?
There’s quite a difference between rapid prototyping on software/hardware versus the human body.
Musk’s approach to developing engineering advances has worked well in the software, aerospace, and vehicular industries. Development on inorganic things is much more predictable, we can isolate variables, and it is easier to understand cause & effect. If you screw up some software on an inorganic system, your program might crash, your rocket might explode, or your car won’t start. These risks can be anticipated and costed fairly well, therefore rapid prototyping has an acceptable risk/reward ratio in that environment.
The human body, on the other hand, is an extremely complex system that we still don’t fully understand. Each person is a unique variation on the model and that changes over time depending on upbringing, diet, exercise, and life experiences. Applying the same engineering approaches from inorganic industries has a much higher risk once you cross into the medical realm. If you have errors in a medical situation, you risk sickening, injuring, or even killing a person. The risk/reward ratio is skewed towards ensuring that human life is protected at all costs.
Using SpaceX as an example, the first three launches failed spectacularly and a fourth failure would have ended the business but fortunately the fourth test was a success. If you’re suggesting that we apply the same risk-taking to Neuralink, are you suggesting that it’s acceptable for the first three patients to die, as long as the fourth is a success?